Less than 10% of people eligible to benefit from obesity jabs including Wegovy can access them, warns the World Health Organization as it publishes its inaugural guidance on the medications.
Given in excess of 1,000,000,000 individuals worldwide now classified as obese, it is calling for more widespread and fairer access to this class of drugs.
Per estimates, over two billion will be obese by 2030 without intervention.
"Our new guidelines acknowledges that excess weight is a lifelong illness that can be treated with comprehensive and lifelong treatment," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and supply-chain constraints are key barriers to widespread availability to the treatments that can aid individuals in losing considerable weight, says the organization.
Skinny Jab Shortage
Even in the current most favorable outlook, the supply of such drugs might only reach approximately 100 million people – less than 10% of those who need them, as stated by the health organization.
The guideline encourages governments and firms to expand access, via approaches like licensing agreements.
A patent on semaglutide – the main component of a leading brand – is set to lapse in multiple nations in 2026.
How Obesity Jabs Work
The injections imitate a biological compound to slow digestion, suppress the appetite and increase satiety so individuals consume fewer calories.
Patients commonly see weight reduction after several weeks of beginning the weekly injections.
Research points to patients may see weight return after a year of halting the medication, as their normal hunger return.
To be overweight or obese elevates your chance for developing health problems, including diabetes, cardiovascular issues, brain attack, and certain cancers.
Excess weight concerns individuals in every country and was linked to 3.7 million deaths worldwide in 2024, according to the health agency.
